Rhythm’s lead asset, IMCIVREE ® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body ...
Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...
BOSTON - Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a $3.4 billion biopharmaceutical company specializing in rare neuroendocrine diseases, has reclaimed the rights to its obesity drug ...
"Based on the unmet need and severity of Prader-Willi syndrome and learnings from our initial study, we plan to initiate an ...
today announced that it reacquired the rights to IMCIVREE ® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing ...
today announced that it reacquired the rights to IMCIVREE ® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing agreement ...
today announced that it reacquired the rights to IMCIVREE® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing agreement ...
Rhythm’s lead asset, IMCIVREE ® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback